Neurizon Therapeutics advances pivotal ALS trial towards 2027 readout

Neurizon Therapeutics (ASX: NUZ) is advancing NUZ-001 through the registrational Phase 2/3 HEALEY ALS Platform Trial in the United States, targeting amyotrophic lateral sclerosis, or motor neurone disease. Recruitment is complete, with 250 participants enrolled across 78 sites and topline